Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Immunomodulatory consequences of ODN CpG-polycation complexes.

Partidos CD, Hoebeke J, Wieckowski S, Chaloin O, Bianco A, Moreau E, Briand JP, Desgranges C, Muller S.

Methods. 2009 Dec;49(4):328-33. doi: 10.1016/j.ymeth.2009.03.005. Epub 2009 Mar 18. Review.

PMID:
19303048
2.

Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties.

Bianco A, Hoebeke J, Godefroy S, Chaloin O, Pantarotto D, Briand JP, Muller S, Prato M, Partidos CD.

J Am Chem Soc. 2005 Jan 12;127(1):58-9.

PMID:
15631447
3.

Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-alpha in the pig and the phenotype of the IFN-alpha producing cells.

Domeika K, Magnusson M, Eloranta ML, Fuxler L, Alm GV, Fossum C.

Vet Immunol Immunopathol. 2004 Sep;101(1-2):87-102.

PMID:
15261695
4.

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM.

J Immunol. 2000 Feb 1;164(3):1617-24.

5.

In vivo immunostimulatory effects of CpG ODN in newborn piglets.

Linghua Z, Xingshan T, Fengzhen Z.

Mol Immunol. 2007 Feb;44(6):1238-44. Epub 2006 Sep 5.

PMID:
16908068
6.

The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN.

Raney SG, Wilson KD, Sekirov L, Chikh G, de Jong SD, Cullis PR, Tam YK.

J Drug Target. 2008 Aug;16(7):564-77. doi: 10.1080/10611860802228756.

PMID:
18686126
7.
8.
9.
11.

Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.

Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA.

J Control Release. 2004 May 31;97(1):1-17. Review.

PMID:
15147800
12.

Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.

Zhang Z, Weinschenk T, Schluesener HJ.

J Neuroimmunol. 2005 Mar;160(1-2):32-40. Epub 2005 Jan 22.

PMID:
15710455
13.

Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.

Kaur H, Jaso-Friedmann L, Leary JH 3rd, Praveen K, Brahmi Z, Evans DL.

Scand J Immunol. 2005 Oct;62(4):361-70.

14.

Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.

Woo SJ, Kim CH, Park MY, Kim HS, Sohn HJ, Park JS, Kim HJ, Oh ST, Kim TG.

Cancer Sci. 2008 May;99(5):1034-9. doi: 10.1111/j.1349-7006.2008.00760.x. Epub 2008 Feb 24.

15.

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.

McCluskie MJ, Weeratna RD, Clements JD, Davis HL.

Vaccine. 2001 Jun 14;19(27):3759-68.

PMID:
11395211
17.

Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.

Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM.

J Immunol. 2001 Sep 1;167(5):2921-8.

18.

CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing.

Chu RS, Askew D, Noss EH, Tobian A, Krieg AM, Harding CV.

J Immunol. 1999 Aug 1;163(3):1188-94.

20.

The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

McCluskie MJ, Weeratna RD, Davis HL.

Vaccine. 2001 Mar 21;19(17-19):2657-60.

PMID:
11257405

Supplemental Content

Support Center